WASHINGTON – Tuesday's trading reflected investors' relief for Amgen Inc., ambiguity about Genzyme Corp. and anxiety over AMAG Pharmaceuticals Inc. on Medicare's release of the final rules governing payments for dialysis services for beneficiaries with end-stage renal disease (ESRD). (BioWorld Today) Read More
